Product news from the 02/20/07 News Brief

Share this article:
Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for propranolol hydrochloride extended-release (ER) capsules in 60mg, 80mg, 120mg and 160mg strengths. Propranolol hydrochloride ER capsules are the generic version of Wyeth’s beta blocker, Inderal LA, which had US sales of approximately $201 million for the same strengths for the 12-month period ended Dec. 31, 2006, according to IMS Health. The FDA has granted priority review status to Gilead Science’s hypertension drug ambrisentan on a priority basis. Ambrisentan is a potential treatment for pulmonary arterial hypertension, a type of high blood pressure that affects the lungs and leads to heart failure. Priority FDA review typically takes six months, only half as long as the one year a drug is typically under review.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions